{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:15:17Z","timestamp":1790680517783,"version":"4.1.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI081449"],"award-info":[{"award-number":["PI081449"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CM20\/00155"],"award-info":[{"award-number":["CM20\/00155"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010556","name":"Xunta de Galicia Conselleria de Economia e Industria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010556","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["PI081449"],"award-info":[{"award-number":["PI081449"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010801","name":"Xunta de Galicia","doi-asserted-by":"publisher","award":["GPC2014\/036"],"award-info":[{"award-number":["GPC2014\/036"]}],"id":[{"id":"10.13039\/501100010801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010801","name":"Xunta de Galicia","doi-asserted-by":"publisher","award":["ED341b 2017\/19"],"award-info":[{"award-number":["ED341b 2017\/19"]}],"id":[{"id":"10.13039\/501100010801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010801","name":"Xunta de Galicia","doi-asserted-by":"publisher","award":["ED431B 2020\/37"],"award-info":[{"award-number":["ED431B 2020\/37"]}],"id":[{"id":"10.13039\/501100010801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.lpm.2021.104071","type":"journal-article","created":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T08:39:32Z","timestamp":1633163972000},"page":"104071","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Familial partial lipodystrophy syndromes"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1268-7538","authenticated-orcid":false,"given":"Ant\u00eda","family":"Fern\u00e1ndez-Pombo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3887-0573","authenticated-orcid":false,"given":"Sof\u00eda","family":"S\u00e1nchez-Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0941-626X","authenticated-orcid":false,"given":"Silvia","family":"Cobelo-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3757-262X","authenticated-orcid":false,"given":"\u00c1lvaro","family":"Hermida-Ameijeiras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ara\u00fajo-Vilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.lpm.2021.104071_bib0001","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1210\/jc.2016-2466","article-title":"The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.lpm.2021.104071_bib0002","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40618-018-0887-z","article-title":"Diagnosis and treatment of lipodystrophy: a step-by-step approach","volume":"42","author":"Ara\u00fajo-Vilar","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.lpm.2021.104071_bib0003","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2147\/DMSO.S130810","article-title":"Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges","volume":"10","author":"Chiquette","year":"2017","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"10.1016\/j.lpm.2021.104071_bib0004","first-page":"170","article-title":"Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety)","volume":"84","author":"Garg","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2021.104071_bib0005","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0002-9343(99)00414-3","article-title":"Lipodystrophies","volume":"108","author":"Garg","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.lpm.2021.104071_bib0006","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1210\/jc.2011-1159","article-title":"Clinical review#: lipodystrophies: genetic and acquired body fat disorders","volume":"96","author":"Garg","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.lpm.2021.104071_bib0007","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1055\/s-2003-38388","article-title":"Phenotypic gender differences in subjects with familial partial lipodystrophy (Dunnigan variety) due to a nuclear lamin A\/C R482W mutation","volume":"35","author":"Ara\u00fajo-Vilar","year":"2003","journal-title":"Horm Metab Res"},{"issue":"11","key":"10.1016\/j.lpm.2021.104071_bib0008","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1210\/jc.2003-031658","article-title":"Patients with familial partial lipodystrophy of the Dunnigan type due to a LMNA R482W mutation show muscular and cardiac abnormalities","volume":"89","author":"Vantyghem","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.lpm.2021.104071_bib0009","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.diabet.2018.09.006","article-title":"Diamenord\u2013Aednl working group. Cardiometabolic assessment of lamin A\/C gene mutation carriers: a phenotype-genotype correlation","volume":"45","author":"Kwapich","year":"2019","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.lpm.2021.104071_bib0010","series-title":"Practical guidelines for the diagnosis and treatment of infrequent lipodystrophies","author":"Ara\u00fajo-Vilar","year":"2020"},{"issue":"12","key":"10.1016\/j.lpm.2021.104071_bib0011","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1056\/NEJMra025261","article-title":"Acquired and inherited lipodystrophies","volume":"350","author":"Garg","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.lpm.2021.104071_bib0012","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/hmg\/9.1.109","article-title":"Nuclear lamin A\/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy","volume":"9","author":"Cao","year":"2000","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.lpm.2021.104071_bib0013","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1152\/physrev.00047.2005","article-title":"Nuclear lamins: laminopathies and their role in premature ageing","volume":"86","author":"Broers","year":"2006","journal-title":"Physiol Rev"},{"issue":"9","key":"10.1016\/j.lpm.2021.104071_bib0014","first-page":"3089","article-title":"LMNA R482Q mutation in partial lipodystrophy associated with reduced plasma leptin concentration","volume":"85","author":"Hegele","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.lpm.2021.104071_bib0015","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/72807","article-title":"LMNA, encoding lamin A\/C, is mutated in partial lipodystrophy","volume":"24","author":"Shackleton","year":"2000","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.lpm.2021.104071_bib0016","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1101\/gad.255968.114","article-title":"Lamins at the crossroads of mechanosignaling","volume":"29","author":"Osmanagic-Myers","year":"2015","journal-title":"Genes Dev"},{"issue":"7","key":"10.1016\/j.lpm.2021.104071_bib0017","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1101\/gad.1652708","article-title":"Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin","volume":"22","author":"Dechat","year":"2008","journal-title":"Genes Dev"},{"key":"10.1016\/j.lpm.2021.104071_bib0018","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1242\/jcs.114.24.4459","article-title":"Nuclear envelope disorganization in fibroblasts from lipodystrophic patients with heterozygous R482Q\/W mutations in the lamin A\/C gene","volume":"114","author":"Vigouroux","year":"2001","journal-title":"J Cell Sci"},{"issue":"2","key":"10.1016\/j.lpm.2021.104071_bib0019","first-page":"129","article-title":"Nurturing the genome: A-type lamins preserve genomic stability","volume":"1","author":"Gonzalez-Suarez","year":"2010","journal-title":"Nucleus"},{"key":"10.1016\/j.lpm.2021.104071_bib0020","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1242\/jcs.114.22.4001","article-title":"Distinct changes in intranuclear lamin A\/C organization during myoblast differentiation","volume":"114","author":"Muralikrishna","year":"2001","journal-title":"J Cell Sci"},{"issue":"1","key":"10.1016\/j.lpm.2021.104071_bib0021","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4161\/nucl.13723","article-title":"Investigating the purpose of prelamin A processing","volume":"2","author":"Davies","year":"2011","journal-title":"Nucleus"},{"issue":"7","key":"10.1016\/j.lpm.2021.104071_bib0022","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/nm1266","article-title":"Genomic instability in laminopathy-based premature aging","volume":"11","author":"Liu","year":"2005","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.lpm.2021.104071_bib0023","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1093\/hmg\/ddq158","article-title":"An accumulation of non-farnesylated prelamin A causes cardiomyopathy but not progeria","volume":"19","author":"Davies","year":"2010","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.lpm.2021.104071_bib0024","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.yexcr.2010.10.014","article-title":"Accumulation of distinct prelamin A variants in human diploid fibroblasts differentially affects cell homeostasis","volume":"317","author":"Candelario","year":"2011","journal-title":"Exp Cell Res"},{"issue":"7058","key":"10.1016\/j.lpm.2021.104071_bib0025","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nature04019","article-title":"Accelerated ageing in mice deficient in Zmpste24 protease is linked to p53 signalling activation","volume":"437","author":"Varela","year":"2005","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.lpm.2021.104071_bib0026","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/jmg.2008.059485","article-title":"Site-dependent differences in both prelamin A and adipogenic genes in subcutaneous adipose tissue of patients with type 2 familial partial lipodystrophy","volume":"46","author":"Ara\u00fajo-Vilar","year":"2009","journal-title":"J Med Genet"},{"issue":"8","key":"10.1016\/j.lpm.2021.104071_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0289-0","article-title":"Altered adipocyte differentiation and unbalanced autophagy in type 2 familial partial lipodystrophy: an in vitro and in vivo study of adipose tissue browning","volume":"51","author":"Pellegrini","year":"2019","journal-title":"Exp Mol Med"},{"issue":"9","key":"10.1016\/j.lpm.2021.104071_bib0028","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1083\/jcb.201701043","article-title":"A lipodystrophy-causing lamin A mutant alters conformation and epigenetic regulation of the anti-adipogenic MIR335 locus","volume":"216","author":"Oldenburg","year":"2017","journal-title":"J Cell Biol"},{"issue":"7","key":"10.1016\/j.lpm.2021.104071_bib0029","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/0092-8674(94)90006-X","article-title":"Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor","volume":"79","author":"Tontonoz","year":"1994","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.lpm.2021.104071_bib0030","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2337\/diabetes.47.4.507","article-title":"PPAR-gamma: adipogenic regulator and thiazolidinedione receptor","volume":"47","author":"Spiegelman","year":"1998","journal-title":"Diabetes"},{"issue":"21","key":"10.1016\/j.lpm.2021.104071_bib0031","doi-asserted-by":"crossref","first-page":"9856","DOI":"10.1073\/pnas.92.21.9856","article-title":"Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR gamma and C\/EBP alpha","volume":"92","author":"Hu","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.lpm.2021.104071_bib0032","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/0092-8674(95)90193-0","article-title":"15-deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma","volume":"83","author":"Forman","year":"1995","journal-title":"Cell"},{"issue":"7305","key":"10.1016\/j.lpm.2021.104071_bib0033","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature09291","article-title":"Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5","volume":"466","author":"Choi","year":"2010","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.lpm.2021.104071_bib0034","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.1210\/jc.2004-0280","article-title":"A single-base mutation in the peroxisome proliferator-activated receptor gamma4 promoter associated with altered in vitro expression and partial lipodystrophy","volume":"89","author":"Al-Shali","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.lpm.2021.104071_bib0035","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1399-0004.2006.00674.x","article-title":"A frameshift mutation in peroxisome-proliferator-activated receptor-gamma in familial partial lipodystrophy subtype 3 (FPLD3; MIM 604367)","volume":"70","author":"Hegele","year":"2006","journal-title":"Clin Genet"},{"key":"10.1016\/j.lpm.2021.104071_bib0036","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2350-7-3","article-title":"Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3)","volume":"7","author":"Francis","year":"2006","journal-title":"BMC Med Genet"},{"issue":"4","key":"10.1016\/j.lpm.2021.104071_bib0037","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1161\/ATVBAHA.112.300962","article-title":"Peroxisome proliferator-activated receptor-\u03b3 mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system","volume":"33","author":"Auclair","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.lpm.2021.104071_bib0038","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1172\/JCI28003","article-title":"PPAR gamma and human metabolic disease","volume":"116","author":"Semple","year":"2006","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.lpm.2021.104071_bib0039","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/ng.3700","article-title":"Prospective functional classification of all possible missense variants in PPARG","volume":"48","author":"Majithia","year":"2016","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.lpm.2021.104071_bib0040","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.bbalip.2019.02.002","article-title":"Gene-gene and gene-environment interactions in lipodystrophy: lessons learned from natural PPAR\u03b3 mutants","volume":"1864","author":"Broekema","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"7","key":"10.1016\/j.lpm.2021.104071_bib0041","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.molmet.2016.05.006","article-title":"Lack of AKT in adipocytes causes severe lipodystrophy","volume":"5","author":"Shearin","year":"2016","journal-title":"Mol Metab"},{"issue":"24","key":"10.1016\/j.lpm.2021.104071_bib0042","doi-asserted-by":"crossref","first-page":"8901","DOI":"10.1073\/pnas.1408523111","article-title":"Mutations disrupting the Kennedy phosphatidylcholine pathway in humans with congenital lipodystrophy and fatty liver disease","volume":"111","author":"Payne","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.lpm.2021.104071_bib0043","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1007487","article-title":"Perilipin deficiency and autosomal dominant partial lipodystrophy","volume":"364","author":"Gandotra","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.lpm.2021.104071_bib0044","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2337\/db14-0104","article-title":"Clinical and molecular characterization of a novel PLIN1 frameshift mutation identified in patients with familial partial lipodystrophy","volume":"64","author":"Kozusko","year":"2015","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.lpm.2021.104071_bib0045","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1210\/jc.2017-02662","article-title":"PLIN1 haploinsufficiency is not associated with lipodystrophy","volume":"103","author":"Laver","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.lpm.2021.104071_bib0046","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1210\/jc.2019-00849","article-title":"Diagnostic challenge in PLIN1-associated familial partial lipodystrophy","volume":"104","author":"J\u00e9ru","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.lpm.2021.104071_bib0047","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/emmm.200900037","article-title":"Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC","volume":"1","author":"Rubio-Cabezas","year":"2009","journal-title":"EMBO Mol Med"},{"issue":"12","key":"10.1016\/j.lpm.2021.104071_bib0048","doi-asserted-by":"crossref","first-page":"6765","DOI":"10.1007\/s11033-013-2793-y","article-title":"Cell death-inducing DFFA-like effector c (CIDEC\/Fsp27) gene: molecular cloning, sequence characterization, tissue distribution and polymorphisms in Chinese cattles","volume":"40","author":"Wang","year":"2013","journal-title":"Mol Biol Rep"},{"issue":"24","key":"10.1016\/j.lpm.2021.104071_bib0049","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1315496","article-title":"Null mutation in hormone-sensitive lipase gene and risk of type 2 diabetes","volume":"370","author":"Albert","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.lpm.2021.104071_bib0050","first-page":"1649","article-title":"A novel LIPE nonsense mutation found using exome sequencing in siblings with late-onset familial partial lipodystrophy","volume":"30","author":"Farhan","year":"2014","journal-title":"Can J Cardiol"},{"issue":"12","key":"10.1016\/j.lpm.2021.104071_bib0051","doi-asserted-by":"crossref","first-page":"8505","DOI":"10.1074\/jbc.M112.417873","article-title":"Mechanisms of action of hormone-sensitive lipase in mouse Leydig cells: its role in the regulation of the steroidogenic acute regulatory protein","volume":"288","author":"Manna","year":"2013","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.lpm.2021.104071_bib0052","doi-asserted-by":"crossref","first-page":"e86870","DOI":"10.1172\/jci.insight.86870","article-title":"Whole-exome sequencing identifies ADRA2A mutation in atypical familial partial lipodystrophy","volume":"1","author":"Garg","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.lpm.2021.104071_bib0053","doi-asserted-by":"crossref","first-page":"e23813","DOI":"10.7554\/eLife.23813","article-title":"Human biallelic MFN2 mutations induce mitochondrial dysfunction, upper body adipose hyperplasia, and suppression of leptin expression","volume":"6","author":"Rocha","year":"2017","journal-title":"Elife"},{"issue":"2","key":"10.1016\/j.lpm.2021.104071_bib0054","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s12020-016-1002-x","article-title":"Type 1 familial partial lipodystrophy: understanding the K\u00f6bberling syndrome","volume":"54","author":"Guill\u00edn-Amarelle","year":"2016","journal-title":"Endocrine"},{"issue":"6","key":"10.1016\/j.lpm.2021.104071_bib0055","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.2337\/diacare.26.6.1819","article-title":"K\u00f6bberling type of familial partial lipodystrophy: an underrecognized syndrome","volume":"26","author":"Herbst","year":"2003","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.lpm.2021.104071_bib0056","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/jmg.23.2.120","article-title":"Familial partial lipodystrophy: two types of an X linked dominant syndrome, lethal in the hemizygous state","volume":"23","author":"K\u00f6bberling","year":"1986","journal-title":"J Med Genet"},{"issue":"1","key":"10.1016\/j.lpm.2021.104071_bib0057","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ng.3714","article-title":"Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance","volume":"49","author":"Lotta","year":"2017","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.lpm.2021.104071_bib0058","first-page":"1776","article-title":"Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety)","volume":"85","author":"Garg","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2021.104071_bib0059","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1042\/BST20110675","article-title":"LMNA-linked lipodystrophies: from altered fat distribution to cellular alterations","volume":"39","author":"Bidault","year":"2011","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.lpm.2021.104071_bib0060","doi-asserted-by":"crossref","first-page":"E1410","DOI":"10.1210\/jc.2013-1297","article-title":"Increased skeletal muscle volume in women with familial partial lipodystrophy, Dunnigan variety","volume":"98","author":"Ji","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.lpm.2021.104071_bib0061","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1210\/jcem.86.5.7500","article-title":"Dyslipemia in familial partial lipodystrophy caused by an R482W mutation in the LMNA gene","volume":"86","author":"Schmidt","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.lpm.2021.104071_bib0062","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.2337\/diacare.26.5.1350","article-title":"Risk factors for diabetes in familial partial lipodystrophy, Dunnigan variety","volume":"26","author":"Haque","year":"2003","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.lpm.2021.104071_bib0063","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.jacl.2016.08.012","article-title":"Familial partial lipodystrophy presenting as metabolic syndrome","volume":"10","author":"Chan","year":"2016","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.lpm.2021.104071_bib0064","first-page":"59","article-title":"Phenotypic heterogeneity in patients with familial partial lipodystrophy (Dunnigan variety) related to the site of missense mutations in lamin A\/C gene","volume":"86","author":"Garg","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2021.104071_bib0065","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1111\/j.1572-0241.2005.00234.x","article-title":"Hepatic steatosis in Dunnigan-type familial partial lipodystrophy","volume":"100","author":"L\u00fcdtke","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.lpm.2021.104071_bib0066","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1210\/jc.2007-2521","article-title":"Fertility and obstetrical complications in women with LMNA-related familial partial lipodystrophy","volume":"93","author":"Vantyghem","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2021.104071_bib0067","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1136\/jmedgenet-2016-104437","article-title":"LMNA-associated partial lipodystrophy: anticipation of metabolic complications","volume":"54","author":"Jeru","year":"2017","journal-title":"J Med Genet"},{"issue":"1","key":"10.1016\/j.lpm.2021.104071_bib0068","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/19491034.2018.1456217","article-title":"Lipodystrophic syndromes due to LMNA mutations: recent developments on biomolecular aspects, pathophysiological hypotheses and therapeutic perspectives","volume":"9","author":"Vigouroux","year":"2018","journal-title":"Nucleus"},{"key":"10.1016\/j.lpm.2021.104071_bib0069","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1161\/01.CIR.103.18.2225","article-title":"Premature atherosclerosis associated with monogenic insulin resistance","volume":"103","author":"Hegele","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2021.104071_bib0070","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2265.2007.03146.x","article-title":"A novel phenotypic expression associated with a new mutation in LMNA gene, characterized by partial lipodystrophy, insulin resistance, aortic stenosis and hypertrophic cardiomyopathy","volume":"69","author":"Araujo-Vilar","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.lpm.2021.104071_bib0071","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1161\/ATVBAHA.113.301933","article-title":"Lipodystrophy-linked LMNA p.R482W mutation induces clinical early atherosclerosis and in vitro endothelial dysfunction","volume":"33","author":"Bidault","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.lpm.2021.104071_bib0072","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ahj.2014.12.021","article-title":"Metabolic and cardiac phenotype characterization in 37 atypical Dunnigan patients with nonfarnesylated mutated prelamin A","volume":"169","author":"Andre","year":"2015","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.lpm.2021.104071_bib0073","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/ng0398-292","article-title":"Localization of the gene for familial partial lipodystrophy (Dunnigan variety) to chromosome 1q21-22","volume":"18","author":"Peters","year":"1998","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.lpm.2021.104071_bib0074","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1086\/302836","article-title":"Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the globular C-terminal domain of lamin A\/C","volume":"66","author":"Speckman","year":"2000","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1016\/j.lpm.2021.104071_bib0075","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00125-004-1360-4","article-title":"Familial partial lipodystrophy associated with compound heterozygosity for novel mutations in the LMNA gene","volume":"47","author":"Savage","year":"2004","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.lpm.2021.104071_bib0076","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1365-2265.2011.04208.x","article-title":"Histological and molecular features of lipomatous and nonlipomatous adipose tissue in familial partial lipodystrophy caused by LMNA mutations","volume":"76","author":"Ara\u00fajo-Vilar","year":"2012","journal-title":"Clin Endocrinol"},{"issue":"12","key":"10.1016\/j.lpm.2021.104071_bib0077","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1210\/jc.2007-0654","article-title":"New metabolic phenotypes in laminopathies: LMNA mutations in patients with severe metabolic syndrome","volume":"92","author":"Decaudain","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.lpm.2021.104071_bib0078","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/cen.13984","article-title":"Phenotypic diversity and glucocorticoid sensitivity in patients with familial partial lipodystrophy type 2","volume":"91","author":"Prata-Resende","year":"2019","journal-title":"Clin Endocrinol"},{"issue":"6","key":"10.1016\/j.lpm.2021.104071_bib0079","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3390\/jcm10061259","article-title":"Variable expressivity in type 2 familial partial lipodystrophy related to R482 and N466 variants in the LMNA gene","volume":"10","author":"Ara\u00fajo-Vilar","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.lpm.2021.104071_bib0080","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1399-0004.2009.01350.x","article-title":"Overlapping syndrome with familial partial lipodystrophy, Dunnigan variety and cardio- myopathy due to amino-terminal heterozygous missense lamin A\/C mutations","volume":"78","author":"Subramanyam","year":"2010","journal-title":"Clin Genet"},{"key":"10.1016\/j.lpm.2021.104071_bib0081","first-page":"376","article-title":"Inflammatory myopathy in the context of an unusual overlapping laminopathy","volume":"62","author":"Guill\u00edn-Amarelle","year":"2018","journal-title":"Arch Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.lpm.2021.104071_bib0082","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12882-018-0913-6","article-title":"The renal manifestations of type 4 familial partial lipodystrophy: a case report and review of literature","volume":"19","author":"Chen","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.lpm.2021.104071_bib0083","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/mus.24157","article-title":"A partial lipodystrophy associated with muscular dystrophy of unknown genetic origin","volume":"49","author":"Carboni","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.lpm.2021.104071_bib0084","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/ajmg.a.37880","article-title":"Homozygous LIPE mutation in siblings with multiple symmetric lipomatosis, partial lipodystrophy, and myopathy","volume":"173","author":"Zolotov","year":"2017","journal-title":"Am J Med Genet A"},{"issue":"1","key":"10.1016\/j.lpm.2021.104071_bib0085","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1530\/EJE-20-1013","article-title":"LIPE-related lipodystrophic syndrome: clinical features and disease modeling using adipose stem cells","volume":"184","author":"Sollier","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"5675","key":"10.1016\/j.lpm.2021.104071_bib0086","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1126\/science.1096706","article-title":"A family with severe insulin resistance and diabetes due to a mutation in AKT2","volume":"304","author":"George","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.lpm.2021.104071_bib0087","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.1093\/hmg\/ddv229","article-title":"Homozygous mutations in MFN2 cause multiple symmetric lipomatosis associated with neuropathy","volume":"24","author":"Sawyer","year":"2015","journal-title":"Hum Mol Genet"},{"issue":"6","key":"10.1016\/j.lpm.2021.104071_bib0088","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jacl.2018.07.009","article-title":"MFN2-associated lipomatosis: clinical spectrum and impact on adipose tissue","volume":"12","author":"Capel","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"10","key":"10.1016\/j.lpm.2021.104071_bib0089","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.2337\/dc18-0978","article-title":"Fat shadows\" from DXA for the qualitative assessment of lipodystrophy: when a picture is worth a thousand numbers","volume":"41","author":"Meral","year":"2018","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.lpm.2021.104071_bib0090","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1210\/clinem\/dgaa137","article-title":"Diagnostic value of anthropometric measurements for familial partial lipodystrophy, dunnigan variety","volume":"105","author":"Vasandani","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.lpm.2021.104071_bib0091","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13023-020-01364-1","article-title":"LipoDDx: a mobile application for identification of rare lipodystrophy syndromes","volume":"15","author":"Ara\u00fajo-Vilar","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.lpm.2021.104071_bib0092","series-title":"Nutritional guide for lipodystrophy","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2021"},{"issue":"4","key":"10.1016\/j.lpm.2021.104071_bib0093","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ecl.2016.06.012","article-title":"Lipodystrophy syndromes","volume":"45","author":"Hussain","year":"2016","journal-title":"Endocrinol Metab Clin N Am"},{"issue":"11","key":"10.1016\/j.lpm.2021.104071_bib0094","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-J\u00e4rvinen","year":"2004","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.lpm.2021.104071_bib0095","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1055\/s-0031-1301284","article-title":"Thiazolidinedione response in familial lipodystrophy patients with LMNA mutations: a case series","volume":"44","author":"Luedtke","year":"2012","journal-title":"Horm Metab Res"},{"issue":"4","key":"10.1016\/j.lpm.2021.104071_bib0096","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-133-4-200008150-00009","article-title":"Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes","volume":"133","author":"Arioglu","year":"2000","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.lpm.2021.104071_bib0097","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.2337\/db17-1236","article-title":"A pharmacogenetic approach to the treatment of patients with PPARG mutations","volume":"67","author":"Agostini","year":"2018","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.lpm.2021.104071_bib0098","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/dme.13527","article-title":"Insulin secretory defect in familial partial lipodystrophy type 2 and successful long-term treatment with a glucagon-like peptide 1 receptor agonist","volume":"34","author":"Banning","year":"2017","journal-title":"Diabet Med"},{"key":"10.1016\/j.lpm.2021.104071_bib0099","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13098-017-0226-0","article-title":"Dipeptidyl peptidase-4 levels are increased and partially related to body fat distribution in patients with familial partial lipodystrophy type 2","volume":"9","author":"Valerio","year":"2017","journal-title":"Diabetol Metab Syndr"},{"issue":"6","key":"10.1016\/j.lpm.2021.104071_bib0100","doi-asserted-by":"crossref","first-page":"450","DOI":"10.7326\/L16-0372","article-title":"Sodium-glucose cotransporter 2 inhibitor improves complications of lipodystrophy: a case report","volume":"166","author":"Kawana","year":"2017","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.lpm.2021.104071_bib0101","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/jdi.12825","article-title":"Treatment of a case of severe insulin resistance as a result of a PIK3R1 mutation with a sodium-glucose cotransporter 2 inhibitor","volume":"9","author":"Hamaguchi","year":"2018","journal-title":"J Diabetes Investig"},{"issue":"1","key":"10.1016\/j.lpm.2021.104071_bib0102","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4158\/EP.15.1.71","article-title":"High-dose insulin therapy: is it time for U-500 insulin?","volume":"15","author":"Lane","year":"2009","journal-title":"Endocr Pract"},{"key":"10.1016\/j.lpm.2021.104071_bib0103","doi-asserted-by":"crossref","first-page":"e69545","DOI":"10.1371\/journal.pone.0069545","article-title":"Adherence to drug label recommendations for avoiding drug interactions causing statin-induced myopathy\u2013a nationwide register study","volume":"8","author":"Settergren","year":"2013","journal-title":"PloS One"},{"issue":"7","key":"10.1016\/j.lpm.2021.104071_bib0104","first-page":"3","article-title":"Efficacy and safety of volanesorsen for the treatment of metabolic complications in patients with familial partial lipodystrophy: results of the BROADEN study","volume":"70","author":"O'Dea","year":"2020","journal-title":"Endocr Abstr"},{"issue":"12","key":"10.1016\/j.lpm.2021.104071_bib0105","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11892-018-1100-7","article-title":"Update on therapeutic options in lipodystrophy","volume":"18","author":"Akinci","year":"2018","journal-title":"Curr Diab Rep"},{"issue":"3","key":"10.1016\/j.lpm.2021.104071_bib0106","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s12020-019-01862-8","article-title":"Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy","volume":"64","author":"Oral","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.lpm.2021.104071_bib0107","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2014-4491","article-title":"Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin","volume":"100","author":"Diker-Cohen","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.lpm.2021.104071_bib0108","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/dom.12606","article-title":"One-year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes","volume":"18","author":"Vatier","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.lpm.2021.104071_bib0109","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1172\/JCI95476","article-title":"Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy","volume":"128","author":"Brown","year":"2018","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.lpm.2021.104071_bib0110","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1210\/js.2019-00103","article-title":"Advanced lipoprotein analysis shows atherogenic lipid profile that improves after metreleptin in patients with lipodystrophy","volume":"3","author":"Kinzer","year":"2019","journal-title":"J Endocr Soc"},{"issue":"3","key":"10.1016\/j.lpm.2021.104071_bib0111","first-page":"659","article-title":"Efficacy and safety of metreleptin in patients with partial lipodystrophy: lessons from an expanded access program","volume":"7","author":"Ajluni","year":"2016","journal-title":"J Diabetes Metab"},{"issue":"3","key":"10.1016\/j.lpm.2021.104071_bib0112","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1210\/jc.2011-2229","article-title":"Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety","volume":"97","author":"Simha","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.lpm.2021.104071_bib0113","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1210\/jc.2018-02787","article-title":"Efficacy of metreleptin treatment in familial partial lipodystrophy due to PPARG vs LMNA pathogenic variants","volume":"104","author":"Sekizkardes","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.lpm.2021.104071_bib0114","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1210\/jc.2019-00200","article-title":"Effects of metreleptin on proteinuria in patients with lipodystrophy","volume":"104","author":"Lee","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.lpm.2021.104071_bib0115","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/cen.12980","article-title":"Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy","volume":"85","author":"Chan","year":"2016","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.lpm.2021.104071_bib0116","first-page":"19","article-title":"The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide","volume":"2020","author":"Akinci","year":"2020","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"10","key":"10.1016\/j.lpm.2021.104071_bib0117","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1210\/jc.2017-01235","article-title":"Roux-en-Y gastric bypass surgery in the management of familial partial lipodystrophy type 1","volume":"102","author":"Melvin","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.lpm.2021.104071_bib0118","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s11605-016-3300-2","article-title":"Successful treatment of an unusual case of FPLD2: the role of Roux-en-Y gastricbypass-case report and literature review","volume":"21","author":"Grundfest-Broniatowski","year":"2017","journal-title":"J Gastrointest Surg"},{"issue":"3","key":"10.1016\/j.lpm.2021.104071_bib0119","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2265.2011.04057.x","article-title":"Successful treatment for the Dunnigan-type familial partial lipodystrophy with Roux-en-Y gastric bypass","volume":"75","author":"Ciudin","year":"2011","journal-title":"Clin Endocrinol"},{"issue":"6","key":"10.1016\/j.lpm.2021.104071_bib0120","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2337\/dc06-0130","article-title":"Effectiveness of gastric bypass surgery in a patient with familial partial lipodystrophy","volume":"29","author":"Utzschneider","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lpm.2021.104071_bib0121","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1097\/DSS.0000000000000870","article-title":"Overview of ATX-101 (Deoxycholic Acid Injection): a nonsurgical approach for reduction of submental fat","volume":"42","author":"Dayan","year":"2016","journal-title":"Dermatol Surg"},{"issue":"2","key":"10.1016\/j.lpm.2021.104071_bib0122","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/17446651.2020.1735360","article-title":"Diagnostic strategies and clinical management of lipodystrophy","volume":"15","author":"Foss-Freitas","year":"2020","journal-title":"Expert Rev Endocrinol Metab"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498221000105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498221000105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:12:05Z","timestamp":1778508725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498221000105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":122,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0755498221000105"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2021.104071","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Familial partial lipodystrophy syndromes","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2021.104071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104071"}}